Patient self-report tool on side effects in cancer clinical trials validated by landmark study
the ONA take:
A landmark study has validated the National Cancer Institute’s Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as an accurate, reliable, and responsive measure of side effects experienced by patients participating in clinical trials. This study compared the PRO-CTCAE with other patient-reported and clinical measures.
More than 1,000 patients from clinical practices across the United States, including seven cancer centers, were recruited to participate in the study.
They were asked to complete the PRO-CTCAE before appointments. Their reports were compared against other established measures of symptoms such as case and quality of life reports and prescription information.
The researchers validated 119 of 125 PRO-CTCAE questions against the established measurement tools usually based on information from providers. Underrepresentation in the study population prohibited evaluation of the five questions that could not be validated.
This study was unique in that more than 100 distinct questions about symptomatic adverse events were validated simultaneously.
The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is accurate, reliable.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|